Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.17
-0.04 (-0.77%)
At close: Apr 28, 2026, 4:00 PM EDT
5.17
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Foghorn Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Foghorn Therapeutics stock have an average target of 11.5, with a low estimate of 9.00 and a high estimate of 13. The average target predicts an increase of 122.44% from the current stock price of 5.17.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2026.
Analyst Ratings
The average analyst rating for Foghorn Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $10 | Buy | Reiterates | $10 | +93.42% | Mar 12, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +151.45% | Mar 10, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $14 → $12 | Strong Buy | Maintains | $14 → $12 | +132.11% | Feb 17, 2026 |
| BTIG | BTIG | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +112.77% | Dec 18, 2025 |
| Stifel | Stifel | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +132.11% | Dec 4, 2025 |
Financial Forecast
Revenue This Year
33.66M
from 30.91M
Increased by 8.89%
Revenue Next Year
40.43M
from 33.66M
Increased by 20.13%
EPS This Year
-1.13
from -1.18
EPS Next Year
-1.11
from -1.13
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 52.5M | 53.8M | ||||||
| Avg | 33.7M | 40.4M | ||||||
| Low | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 69.9% | 59.8% | ||||||
| Avg | 8.9% | 20.1% | ||||||
| Low | - | -41.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.97 | -0.70 | ||||||
| Avg | -1.13 | -1.11 | ||||||
| Low | -1.54 | -1.53 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.